Novo targets oral macrocycles with $1.4bn Orbis partnership - Pharmaceutical Technology

The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics. The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics. Macrocycles are a large ring-shaped molecule that have metabolic stability and an ability to conduct protein-protein interactions that small molecules cannot. Credit: theromb/Shutterstock.com. Novo has teamed up with macrocycle specialist Orbis Medicines in a deal worth up to $1.4bn, marking an effort by the Danish pharma to bolster its cardiometabolic pipeline after a series of setbacks. Under the…

Source: Pharmaceutical Technology